Bibliography
- Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. Springer; New York, NY; 2009
- Vergnoble N, Chignard M. Proteases and their receptors in inflammation. Springer; New York, NY; 2011
- Desnoyers LR, Vasiljeva O, Richardson JH, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 2013;5:164-73
- LeBeau AM, Lee M, Murphy ST, et al. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci USA 2013;110:93-8
- Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59
- Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152-9
- Aster JC. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol 2012;30:2418-20
- Sagert J, West J, Vasiljeva O, et al. Tumor-specific inhibition of jagged-dependent Notch signaling using a probody™ therapeutic. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 19 – 23 October 2013; Boston, Philadelphia: AACR. Mol Cancer Ther 2013;12(11 Suppl):abstract C158
- Panowski S, Bhakta S, Raab H, et al. Site-specific antibody conjugates for cancer therapy. MAbs 2014;6:1-12
- Gerber H-P, Koehn FE, Abraham RT. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 2013;30:625-39
- Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J Clin Oncol 2000;18:2282-92
- Stone JD, Aggen DH, Schietinger A, et al. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell engagers (BiTEs). Oncoimmunology 2012;1:863-73
- Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skn reactions: the randomized EVEREST study. J Clin Oncol 2012;10:2861-8
- Azzopardi N, Lecomte T, Ternant D, et al. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res 2011;17:6329-37
- Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutations in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119:3000-10